BMC Infectious Diseases (Jul 2018)

Extra-haematological manifestations related to human parvovirus B19 infection: retrospective study in 25 adults

  • Marion Dollat,
  • Benjamin Chaigne,
  • Grégoire Cormier,
  • Nathalie Costedoat-Chalumeau,
  • François Lifermann,
  • Alban Deroux,
  • Emilie Berthoux,
  • Emmanuelle Dernis,
  • Thomas Sené,
  • Gilles Blaison,
  • Olivier Lambotte,
  • Benjamin Terrier,
  • Jérémie Sellam,
  • Luc De Saint-Martin,
  • Laurent Chiche,
  • Nicolas Dupin,
  • Luc Mouthon

DOI
https://doi.org/10.1186/s12879-018-3227-1
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background To describe extra-haematological manifestations associated with human parvovirus B19 (HPV-B19) infection. Methods We conducted a nationwide multicentre study to retrospectively describe the characteristics and outcome of extra-haematological manifestations in French adults. Results Data from 25 patients followed from 2001 to 2016 were analysed. Median age was 37.9 years (range: 22.7–83.4), with a female predominance (sex ratio: 4/1). Only 3 patients had an underlying predisposing condition (hemoglobinopathy or pregnancy). The most common manifestations were joint (80%) and skin (60%) involvement. Four patients (16%) had renal involvement (endocapillary proliferative or membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis). Three patients (12%) had peripheral nervous system involvement (mononeuritis, mononeuritis multiplex, Guillain-Barré syndrome) and 2 (8%) presented muscle involvement. Other manifestations included hemophagocytic lymphohistiocytosis (n = 1), myopericarditis and pleural effusion (n = 1), and lymphadenopathy and splenomegaly mimicking lymphoma with spleen infarcts (n = 1). Immunological abnormalities were frequent (56.5%). At 6 months, all patients were alive, and 54.2% were in complete remission. In 2 patients, joint involvement evolved into rheumatoid arthritis. Six patients (24%) received intravenous immunoglobulin (IVIg), with a good response in the 3 patients with peripheral nervous system involvement. Conclusions HPV-B19 infection should be considered in a wide range of clinical manifestations. Although the prognosis is good, IVIg therapy should be discussed in patients with peripheral nerve involvement. However, its efficacy should be further investigated in prospective studies.

Keywords